Skip Navigation LinksHome > May 1996 - Volume 84 - Issue 5 > Concurrent Spinal Infusion of MK801 Blocks Spinal Tolerance...
Anesthesiology:
Laboratory Investigation

Concurrent Spinal Infusion of MK801 Blocks Spinal Tolerance and Dependence Induced by Chronic Intrathecal Morphine in the Rat

Dunbar, Stuart MB; Yaksh, Tony L. PhD

Free Access
Article Outline
Collapse Box

Author Information

Collapse Box

Abstract

Background: MK801, an N-methyl-D-aspartate receptor antagonist, has recently been reported to attenuate tolerance to, and withdrawal from morphine. This study analyzes tolerance and withdrawal in a chronic intrathecal coinfusion model of morphine and MK801.
Methods: Intrathecal catheters, attached to 7-day miniosmotic infusion pumps, were implanted in rats and infused with saline, 20 nM/h morphine, MK801 (10 and 3 nM/h) + morphine; and 10 nM/h MK801. Analgesia was measured on the hot plate daily. On the day 7, groups received 3 mg/kg intraperitoneal naloxone and six signs of withdrawal were assessed: vocalization to air motion or light touch, abnormal posture, spontaneous vocalization, escape attempts, "wet dog shakes," and ejaculation. Similar groups were tested only on days 1 and 7. Intrathecal morphine dose-response curves were obtained on day 8. A separate morphine-tolerant group received 10 nM MK801 on day 7. Rats from each group received 10 nM intrathecal morphine 1 week later.
Results: Coinfusion of MK801 with morphine resulted in a dose-dependent preservation of effect, and attenuated three of six signs of withdrawal. Coinfusion of MK801 (10 and 3 nM/h) prevented the reduction of potency observed with morphine alone. ED50 values (maximum percent effect, nM morphine) were: saline (16), morphine (496), MK801 (10 nM/h) + morphine (4), and 10 nM/h MK801 (0.3). Acute administration of MK801 was ineffective in restoring sensitivity to morphine. One week after cessation of infusion, there was no significant difference between groups.
Conclusions: Chronic spinal MK801 attenuates tolerance to, and withdrawal from spinal morphine in a dose-dependent fashion, supporting the hypothesis that N-methyl-D-aspartate receptor activity plays a role in the reorganization of spinal function produced by chronic opioid receptor activation. Chronic intrathecal MK801 appears to sensitize the spinal cord to intrathecal morphine.
RECENT studies in rats using the hot plate or tail flick tests to assess antinociception, have shown that antagonism at the N-methyl-D-aspartate (NMDA) receptor site attenuates tolerance and withdrawal otherwise observed after chronic morphine administration. [1-4] These initial systemic studies found that: (1) MK801 given alone, was without significant antinociceptive effect, (2) MK801 administered to rats already rendered morphine-tolerant was largely ineffective in restoring sensitivity to morphine, (3) MK801 need not be present at the time of testing to demonstrate attenuation of tolerance to morphine, and (4) MK801 could prevent tolerance for periods as long as 12 days when coadministered with morphine. While without effects by itself, it is not clear whether MK801 augments antinociception when administered simultaneously with morphine. Some studies indeed report an additive effect during the initial period of tolerance induction, [4,5] whereas other investigators have not reported this interaction when MK801 was administered after an initial period of opioid exposure. [1,6].
The ability of MK801 to prevent morphine tolerance also has been demonstrated at spinal sites when administered to spinalized rats, [1,6] and in intrathecal models of daily coadministration of MK801 and morphine. [7,8] While these provide strong support for the role of an NMDA receptor in opioid tolerance, these models used once daily intrathecal injections to investigate the ability of MK801 to prevent tolerance, and thus involve daily handling, a factor that may be implicated in associative learning and tolerance. [9] In addition, it is possible that daily injections can result in a state of intermittent withdrawal in the period preceding each successive injection of morphine; a factor we believe may be responsible for what has been described as "hyperalgesia" observed during the course of induction of tolerance, where rats have been reported to develop hypersensitivity to a thermal noxious stimulus during daily bolus delivery of morphine. [7].
In previous work, we characterized the loss of antinociceptive activity of opioids as a consequence of continuous spinal infusion using chronically implanted spinal catheters coupled to subcutaneous osmotic pumps. [10-13] In these studies, the initiation of a chronic infusion resulted in an initial concentration-dependent increase in escape latency, which declined daily, returning to baseline by 4-6 days. This loss of effect occurred in the absence of intervening testing and, in spite of a continued and measured presence of spinal drug. Importantly, consistent with the inactivation of opioid-sensitive sites, examination of the animals' responses to a bolus "probe" dose of morphine after chronic exposure revealed a right shift in the probe drug dose-response curve, with the magnitude of the right shift being proportional to the infusion concentration of the toleragen. That this right shift is not a consequence of a general dysfunction of the animal, is indicated by the absence of a similar change in sensitivity to probe drugs acting on a separate receptor (e.g., alpha2 agonists). [10].
The specific aims of the current study were: (1) to attempt to reproduce previous findings and assess the effects of NMDA receptor antagonism on this model of continuous spinal opioid exposure, as well as the effects of daily testing on this model; (2) to quantify the magnitude of the tolerance development induced by chronic opioid exposure by assessing the degree of shift in the bolus dose-response curves of each group after a week of infusion ("probe dose-response curve"); (3) to assess the duration of effect of MK801 on morphine tolerance after its discontinuation; and (4) to assess naloxone-precipitated withdrawal in MK801-treated morphine-tolerant rats in an intrathecal model.
Back to Top | Article Outline
Methods
Animals
Approval for this study was obtained from the University of California San Diego Animal Care Committee. Male Sprague-Dawley rats (weighing 350-400 g) were implanted and thereafter housed in individual standard cages at room temperature on a 12 h/12 h light/dark cycle (lights on 7:00 AM). Testing was performed during the light cycle at 12:00 noon. Animals had free access to food and water. Each rat was implanted as described later with a subarachnoid catheter attached to a subcutaneous osmotic pump filled with saline or drug(s). Rats were assigned to one or the other group randomly. All rats received a 7-day infusion and after testing on the last day were killed by an overdose of barbiturate.
Back to Top | Article Outline
Preparation of the Catheter with Infusion Pump and Implantation
The preparation of the catheter has been described previously. [13] In brief, a 16-cm length of PE-10 tubing is connected by heat fusing with a hot air jet to a 2-cm length of PE-60 tubing. A 1-cm piece of Silastic tubing (Tuzik, Norwell, MA) previously soaked in chloroform to increase its internal diameter, is then passed over both ends of the PE-10 tubing so as to form a loop at a distance of 3 cm from the end of the PE10 tubing fused to the PE-60. The long end of the catheter is stretched to reduce diameter, soaked in alcohol (70%) overnight, and cut to a length of 9 cm from the silastic tubing. Alzet osmotic minipumps (model 2001 delivering 1 micro liter/h; Alza, Palo Alta, CA) were filled with drug(s) or saline and attached to the saline-flushed catheter. This pump is designed to deliver a constant infusion of 1 micro liter/h for 7 days after an initial activation period in the animal of 4 h. In vitro pilot studies at 37 degrees C confirmed the accuracy of the pump with catheter attached. The catheter and pump were implanted between the hours of 9:00 AM and 12:00 PM, according to the procedure originally described for chronic catheterization of the rat spinal cord, [14] with the additional modification of the subcutaneous osmotic pump. In brief, animals were anesthetized with halothane and placed in a stereotaxic head holder. A midline incision is made to expose the atlantooccipital membrane. The membrane is pierced and the PE-10 end of the catheter is passed intrathecally to a distance of 8.5 cm, that is, caudal to the level of the thoracolumbar junction. The pump is then attached to the PE-60 end of the catheter and implanted subcutaneously in a pouch to lie just behind one or the other shoulder. A 14-G needle is used to make a small hole in the forehead. The loop end of the catheter is passed through this hole. This PE-10 loop can then be cut and used to administer external doses of drug at the end of the 7-day infusion period. The wound is sutured, including a loose ligature at the base of the loop to prevent it from moving. Animals fully recovered 15-30 min after implantation. Those showing any signs of motor impairment were killed with an overdose of barbiturate.
Back to Top | Article Outline
Drugs and Injection
The following drugs were used for continuous spinal infusion: morphine sulfate (Merck, Sharp and Dohme, West Point, PA), and (+)MK801 hydrogen maleate (Research Biochemicals, Natick, MA). Drugs were dissolved in sterile normal saline. Drug doses, calculated as the free base, were expressed in nanomoles per hour (nM/h) for the infusion concentrations, or nanomoles per rat for the postinfusion dose-response studies. Morphine infusion concentration was 20 nM/micro liter/h in all animals receiving morphine because this dose was found in previous experiments to have yielded a near maximal increase in hot plate latency on day 1 after implantation. [10].
Back to Top | Article Outline
Experimental Paradigms
The study was divided into two phases. Phase 1 was directed toward defining the change in response over time during chronic morphine infusion and the magnitude of the withdrawal response. Phase 2 was designed to assess the effects of daily handling on the nociceptive threshold at 7 days and to assess the subsequent right shift in probe dose-response curve as a function of treatment group.
Phase 1. In the first phase, animals were first tested on the hot plate and then implanted. Testing was carried out daily on the hot plate between the hours of 10:00 AM and 12:00 noon from day 0, the day of implantation, to day 7; i.e., at the end of 7 days of infusion. In this phase of the experiment, two doses of MK801 were chosen, 3 nM/h and 10 nM/h as a coinfusion with morphine. The higher MK801 dose of 10 nM/h was found to have the maximal effect in attenuating tolerance with the least number of animals expressing side effects when administered in a pilot study. In preliminary studies, we observed that MK801 doses exceeding 15 nM/h resulted in weight loss and motor weakness, whereas doses of 1 nM/h or less were found to have little effect on morphine tolerance. Groups were thus examined with 3 nM/h MK801 + morphine sulfate, 10 nM/h MK801 + morphine sulfate, 10 nM/h MK801, morphine sulfate, and saline. A separate group of each treatment group of rats were tested only on days 0, 1, and 7 to assess if there was any effect on latencies from daily testing itself.
Finally, a group infused with morphine sulfate alone was given an intrathecal bolus dose of 10 nM MK801 on day 7 to determine whether acute intrathecal MK801 would restore morphine sensitivity in morphine-tolerant rats. Bolus doses higher than 10 nM produced side effects and thus were not studied.
To assess dependency in these animals, all rats in those groups tested daily on the hot plate were then entered into a withdrawal study as follows. At the end of the 7-day infusion period; i.e., on day 7 at 12:00 noon, rats from each group were given 0.3 mg/kg intraperitoneal naloxane and observed for a period of 1 h, in a circular transparent observation chamber, for the presence or absence of signs of withdrawal. The observer was blinded as to what group to which each rat belonged. Signs of withdrawal chosen for assessment had been previously determined to be prevalent in animals infused for 7 days with intrathecal morphine that received the same dose of naloxone. These signs were: (1) vocalization in response to air motion produced by blowing gently on the rat through a straw three times, or in response to light touch with a 3-cm piece of PE-10 tubing; (2) Spontaneous vocalization; (3) abnormal posture indicated by hind paw lift; 4. ejaculation; 5. had shaking, also often called "wet dog head shakes"; 6. escape attempts--one or more attempt to escape from the chamber. Animals were killed and dissected to assess the integrity of the catheter and the infusion system. Any animal found to have a blocked or misplaced catheter was eliminated from the study.
Phase 2. In phase 2, all groups were tested on the hot plate only on days 1, 2, and 7. Implanted rats were then entered into the following study. On day 7, after testing on the hot plate at approximately 12:00 noon, the external loop of catheter was cut, and the intrathecal part of the catheter flushed with 10 micro liter sterile normal saline. On day 8, 24 h after stopping the infusion, a single probe dose of intrathecal morphine was administered. Based on preliminary studies, rats were given one of the following intrathecal probe doses of morphine; those infused with saline were given either 1 nM, 10 nM, or 100 nM/10 micro liter morphine; those infused with morphine alone were given 1 nM, 10 nM, 30 nM and 100 nM/10 micro liter morphine; those infused with MK801 10 nM/h + morphine were given either 0.01 nM, 0.1 nM, 1 nM, or 10 nM/micro liter morphine; those infused with MK801 alone were given either 0.01 nM, 0.1 nM, 1 nM, or 10 nM/micro liter morphine. Hot plate latencies were measured at 0, 30, 60, and 120 min. This assignment was continued until at least four or more rats in each group were obtained for each intrathecal probe dose, generating a dose-response curve for each group. Each rat was used only once.
Finally, rats from each of these groups were retested 1 week later, after cessation of infusion, to assess their response to an intrathecal probe dose of 10 nM of morphine on the hot plate. Hot plate latencies were measured at 0, 15, 30, and 60 min.
Back to Top | Article Outline
Antinociceptive Testing and Data Analysis
The effects of intrathecal infusions were assessed by the hotplate (HP) test. The HP apparatus was a water bath, the stainless steel surface of which was the test surface, This surface was maintained at a temperature of 52.5+/-0.5 degree C by a proportional feedback controller. Licking of either hind paw, jumping with two feet off the hot plate, extreme agitation, or vocalization was taken as the end point. A cutoff time of 60 s was set to avoid tissue damage. Rats were assessed once for daily testing. For the second phase of the experiment after administration of the probe dose of morphine, testing was performed at 0, 30, 60, and 120 min.
Hot plate data are expressed either as mean latencies for each group, or as maximum percent effect (MPE). Maximum percent effect is calculated as follows: Equation 1 where postdrug latency is the response measured at the particular time after initiation of infusion or after intrathecal dose of probe drug. Baseline is the preinfusion or preprobe latency, and the cutoff time is 60 s.
Equation 1
Equation 1
Image Tools
Back to Top | Article Outline
Statistics
Analysis of the dose-response curves and statistics were obtained with computer software programs (Abacus Concepts, StatView, Abacus Concepts, Berkeley, CA). Where applicable, data from hot plate testing, i.e. absolute latencies or calculated %MPE, were analyzed using one- or two-way analysis of variance (ANOVA) to detect differences between groups. When differences were found, these findings were subjected to Scheffe's F test (significant at 95%). Unless stated otherwise, single points of comparison were made using a standard paired or unpaired t test. Using linear regression, calculation of the ED50 (95% confidence intervals) test for relative potency was carried out where applicable. The tolerance ratio (the ratio of ED50 in drug-infused animals to ED50 of saline infused animals), and 95% confidence intervals were calculated. Differences yielding critical values corresponding to P < 0.05 were considered statistically significant.
Back to Top | Article Outline
Results
Daily Hot Plate Response Latencies in Chronically Infused Rats
Saline-infused Rats. There was no significant difference between latencies on days 1 and 7 in rats that were tested daily, i.e., on days 0 through 7 (phase 1 rats; 15+/-1 vs. 15+/-1 s, n = 5, P > 0.1; Figure 1(A)), or in those that were tested only on days 0, 1, and 7 (phase 2 rats) (15+/-1 vs. 17+/-1 s, n = 11, P > 0.1; Figure 1(B)). Neither was there a significant difference between these two saline-infused groups (ANOVA, P > 0.1), demonstrating no significant effect after day 1, from implantation, infusion of the vehicle saline, or from daily testing. All saline-infused rats (n = 16), however, did show a small, but statistically significant rise in latencies on day 1 compared to baseline values on the day 0; (12+/-1 vs. 15+/-1 s, P < 0.05).
Figure 1
Figure 1
Image Tools
Morphine-infused Rats. There was no significant difference between morphine-infused rats tested daily (n = 15), and those tested only on days 0, 1, and 7 (n = 15; ANOVA P > 0.1; Figure 1). All morphine-infused rats, i.e., those included in phases 1 and 2 of the study, showed a maximal increase in HP latencies on day 1 over baseline on day 0 (45+/-3 vs. 13+/-1 s), returning to near baseline values on day 7 (day 7; 16+/-1 vs. day 0; 13+/-1 s). There was no significant difference between latencies of all saline-infused rats (n = 16) and all morphine-infused rats (n = 30) on day 7 (16+/-1 vs. 16+/-1 s, ANOVA P > 0.1).
On day 8, 24 h after stopping the infusion, latencies of morphine-infused rats, tested only on days 0, 1, and 7, were significantly less than those on day 7 (day 8, 11+/-1 vs. day 7, 15+/- 1 s, n = 15, P < 0.05, Scheffe) and significantly less than those of the group of similarly tested rats receiving saline, on day 8 (16+/- 2 s, n = 11, P < 0.05, Scheffe; Figure 1(B)), demonstrating an increased thermal sensitivity in the morphine-infused rats only after discontinuation of the morphine infusion.
Rats infused with 10 nM/h MK801. Although 10 nM/h MK801-infused rats tested daily showed a small but significant increase in latencies on days 0, 1, 4, and 6, as compared to saline-infused rats tested daily (ANOVA, P < 0.05, Scheffe), there was no significant difference in calculated % MPE between these two groups (ANOVA P > 0.1; Figure 1(A)). Also, there was no significant difference between the same group of MK801-infused rats on day 0, as compared to those on day 7 (day 0, 16 +/-2 vs. day 7, 20+/-3 s, P > 0.1), or compared to those of saline-infused rats on day 7 (15+/-1 s, P > 0.1). In addition, there was no significant difference between rats infused with MK801 alone and tested daily (n = 6), as compared to a separate group of rats infused with MK801 alone, but only tested on days 0, 1, and 7 (n = 17, ANOVA, P > 0.1, Figure 1(B)).
MK801 + Morphine-coinfused Rats. Rats coinfused with 10 nM/h MK801 + 20 nM/h morphine that were tested daily showed a comparable increase in latencies on day 1 (37+/-5 s, n = 11) that was not significantly different from morphine-infused rats that were also tested daily (40+/-4 s, n = 15, P > 0.1, Figure 2). Latencies remained elevated in 10 nM/h MK801 + morphine-coinfused rats tested daily from days 1 through 7, and there was no significant difference between days 1 and 7 (37+/-5, vs. 37+/-4 s, P > 0.1, n = 11). On day 8, 24 h after the infusion was stopped, latencies in rats tested only on days 0, 1, and 7, declined to near baseline values with only a small, but significant increase as compared to baseline on day 0 (18+/-1 vs. 13+/-1 s, n = 19, P < 0.05). However, these latencies were not significantly different from saline-infused rats tested similarly (16 +/-2, n = 11, P > 0.1), but they were significantly higher than morphine-infused rats tested similarly (11+/-1 s, n = 15; Figure 1(B)).
Figure 2
Figure 2
Image Tools
Thus, coinfusion of MK801 at 10 nM/h with morphine resulted in maintenance of elevated latencies during infusion, which, on cessation of infusion, returned toward baseline but did not go below baseline values, as seen in morphine-infused rats.
Latencies in rats tested daily and infused with 3 nM/h MK801 and 20 nM/h morphine (n = 9), were significantly increased over saline-infused rats, except on days 3 and 7 (ANOVA P < 0.05, Scheffe; Figure 2). These latencies also were significantly increased over those of morphine-infused rats from days 4 through 7 (ANOVA P < 0.05, Scheffe). Latencies observed in this group were numerically less but not significantly different than those of rats coinfused with the larger dose of 10 nM/h MK801 + morphine, except on day 1 (ANOVA P > 0.05).
Morphine-infused Rats Given Intrathecal MK801 Acutely on Day 7. Rats infused with morphine alone that were given a 10-nM bolus of intrathecal MK801 on day 7 (n = 4), failed to showed a significant increase in latencies when measured at 0, 30, 60, and 120 min; (17 +/-0.4 vs. 20+/-1 vs. 19.5+/-1, P > 0.1), thus demonstrating a lack of acute effect of MK801 in restoring sensitivity to morphine (Figure 3).
Figure 3
Figure 3
Image Tools
Withdrawal Studies. All groups tested daily on the hot plate were entered into a withdrawal study receiving 0.3 mg/kg naloxone intraperitoneally on day 8 (Figure 4). None of the rats infused with saline (n = 5) showed any of the six withdrawal signs examined. Two rats in the group that received MK801 alone (n = 6) showed one sign of withdrawal each. In contrast, morphine-infused rats (n = 7), all exhibited three or more of the six signs of withdrawal assessed. MK801 and morphine-coinfused rats (n = 11) showed a significant reduction in three of the six signs of withdrawal; i.e., vocalization to air motion or light touch, spontaneous vocalization, and paw lift when compared to morphine-infused rats (P < 0.05). MK801 (3 nM/h) and morphine-coinfused rats (n = 8) showed only a significant reduction in one sign of withdrawal, i.e., ejaculation when compared to morphine-infused rats.
Figure 4
Figure 4
Image Tools
Back to Top | Article Outline
Probe Dose-response curves
After severing the pump catheter connection on day 7 and flushing the catheter with 10 micro liter saline, 24 h was allowed to elapse and the rat was then given one of several doses of intrathecal morphine to generate the probe dose response curve.
Saline and MK801-infused Rats and Probe Dose Response. Twenty-four hours after terminating saline infusion, bolus doses of intrathecal morphine revealed a monotonic dose response curve with an ED sub 50 of %MPE of 11 nM. In rats receiving MK801, the intrathecal morphine %MPE probe dose-response curve showed a 36-fold parallel left shift, as compared to saline-infused rats. The ED50 as measured by percent area under the curve (%AUC) also was decreased by 26-fold showing an increased duration of effect, as well as peak effect (Figure 5 and Table 1).
Figure 5
Figure 5
Image Tools
Table 1
Table 1
Image Tools
Morphine-infused Rats and Probe Dose Response. The intrathecal morphine %MPE probe dose-response curve in rats treated previously with 20 nM/h intrathecal morphine infusions displayed a significant right shift, such that the ED50 was increased by a factor of 14 as compared to the dose-response curve of saline-infused rats (Figure 5(A) and Table 1). Probe doses greater than 150 nM of morphine began to produce a hyperalgesic response (e.g., spontaneous vocalization) as previously described. [15] Thus, it was not possible to test even a half log dose increase of intrathecal morphine probe over that of the highest dose given, i.e. 100 nM. The ED50 as measured by %AUC also was increased by a factor of 200 as compared to saline-infused rats (Figure 5(B) and Table 1). This indicates that in morphine-tolerant animals, the peak effect as well as the duration of effect of the probe dose of spinal morphine is considerably reduced.
Morphine + MK801-infused Rats and Probe Dose Response. MK801 + morphine sulfate-coinfused rats showed a significant left shift in their dose-response curve, as measured by %MPE, such that the ED50 was significantly decreased by a factor of 60 as compared to that of morphine-infused rats (Figure 5(A)). ED50 as measured by %AUC was also significantly decreased by a factor of 264 as compared to morphine-infused rats (Figure 5(B)). ED50 as measured by %MPE or %AUC showed a small but not significant decease compared to saline-infused rats (Table 1). This indicates that in rats infused with morphine and MK801, sensitivity to peak effect and duration of morphine was not significantly different from that of saline-infused rats.
Response to Single Intrathecal Probe Dose of Morphine 7 Days after Cessation of Infusion. Four or more rats in each group infused with saline, morphine, MK801 + morphine, and MK801 alone, and tested on days 0, 1, 7, and 8, were given a 10-nM intrathecal probe dose of morphine 7 days after discontinuation of their infusion, i.e., on day 15. There was no significant difference in HP latencies as measured by %MPE or %AUC between saline-infused rats (n = 4) and MK801 + morphine-infused rats (n = 4), MK801-infused rats (n = 5), or morphine-infused rats (n = 8) (P > 0.1, ANOVA, Figure 6). Thus, there was no residual evidence of hypersensitivity to morphine 7 days after termination of MK801 infusion, or of tolerance in morphine-infused rats when compared to saline control rats.
Figure 6
Figure 6
Image Tools
Back to Top | Article Outline
Discussion
Previous work has shown that the administration of MK801 can attenuate tolerance to, and withdrawal from, chronic systemic and spinal morphine administration. [1-4,7,8,16] These previous studies, while insightful, typically employ bolus drug delivery or pellet systems that produce widely changing drug concentrations over a brief period of time. To define the properties of the reported effects of NMDA antagonism on opioid tolerance and dependence, we initiated studies employing the well-characterized model of continuous spinal delivery in the rat. Continued exposure of the spinal cord to a fixed concentration of morphine will result in (1) a progressive loss of spinal opioid receptor-mediated antinociception, with a reliable right shift in the dose-response curve for bolus doses of spinal morphine, [10] and (2) signs of withdrawal after precipitation with naloxone, including vocalization to touch, spontaneous vocalization, abnormal posturing, ejaculation, head shaking, or escape attempts. Intrathecal MK801, a use-dependent blocker of the NMDA ionophore, has no effect on the hot plate response, [7] and will not acutely increase the response latency when given in a rat that has been rendered tolerant by chronic exposure to spinal morphine (current study). However, as demonstrated in the current study, when delivered concurrently with morphine, but not as a bolus after loss of opioid activity, it preserves, in a dose-dependent fashion, the antinociception produced by morphine. These results suggest that during continued opioid exposure there is a change in spinal function leading to a reduction in opioid responsiveness and this reorganization is mediated in an essential fashion by the activation of the NMDA glutamate receptor.
Back to Top | Article Outline
Spinal Opioid Tolerance
In the current model, loss of effect, and a right shift in the dose-response curve to intrathecal morphine, was observed in morphine-infused animals that were tested daily or tested only at the beginning and end of the infusion. [12,13] Thus, it appears that the significant effects are not attributable to behavioral conditioning, where pairing of drug administration and environmental cues may play a role in the apparent progressive loss of drug effect. [17] Changes in spinal morphine kinetics and metabolism also appear unlikely to account for the progressive reduction. [10] Similarly, the ability to induce antinociception when agonists for other receptors are delivered in a morphine-tolerant rat appears to exclude a "nonspecific" change in nociceptive processing. Pharmacologically, chronic opioid exposure results in a right shift of the dose-response curve and frequently a reduction in the maximum achievable effect. Importantly, the magnitude of the right shift is inversely proportional to the intrinsic efficacy of the agonist as determined in experiments with spinally delivered micro-opioid and alpha2 adrenoceptor agonists. [18-20] Such changes are consistent with a reduction in the number of receptors, or in coupling of the receptors to the intracellular second messengers that mediate the respective actions of these agonists. Binding studies often have shown a modest reduction in binding with chronic opioid exposures, but these results have not been consistent. [21-24].
Back to Top | Article Outline
Mechanisms of N-methyl-D-aspartate Antagonist-Morphine Interaction
The current studies were carried out only with MK801. However, results with systemic delivery also have been observed with a structurally distinct competitive NMDA antagonist, LY-274614. [16] This joint action supports the likely role for the role of the NMDA ionophore with which these two agents are known to interact with high affinity. [25].
Hot plate latencies in morphine + MK801-, and MK801-infused rats returned to baseline after discontinuation of infusion. This argues against any permanent neurologic effect that might have accounted for the observed persistence of antinociception. Any synergistic action between MK801 and morphine would appear unlikely because: (1) MK801 given alone had no observable effect, (2) MK801 when administered with morphine as a coinfusion had no effect on latencies on the second day of infusion (3) MK801 when delivered as a bolus failed to increase hot plate latencies in the morphine-tolerant rat (4) Investigations by other previous studies have shown no simple additive effect of MK801 and morphine in intrathecal studies, [7] in systemic studies, [1] or in spinalized rats. [6] In the formalin test in which MK801 is active, bolus spinal injections of MK801 and morphine interact at most in an additive fashion. [26] These data emphasize that the ability of MK801 to maintain an opioid effect as long as 7 days does not represent an acute reversal of possible changes initiated by spinal morphine, but reflects prevention of the evolution of the opioid-tolerant state. This concept of a prevention of the development of a change in spinal function also is supported by the observation that cotreatment with MK801 prevented the appearance of a precipitated withdrawal. Importantly, however, naloxone-precipitated withdrawal signs in the rat chronically exposed to spinal morphine is attenuated by acutely delivered intrathecal MK801. [27] Thus, these studies jointly suggest that chronic, but not acute antagonism of the NMDA receptor will prevent the evolution of tolerance and dependence, whereas acute antagonism will only prevent manifestations of the opioid withdrawal state, and not reverse an established tolerant state.
The apparent preservation of the effects of morphine in the presence of MK801 may reflect a concurrent increase in sensitivity to opioid receptor occupancy. Thus, in the current studies, we unexpectedly observed that the chronic delivery of MK801 alone resulted in a left shift of the morphine dose response that was present 24 h, but not 7 days after termination of chronic delivery. This has not, to our knowledge, been hitherto reported, and may have direct clinical implications should drugs of this class enter clinical practice. The persistence of this effect at a time in which MK801 was not present, emphasizes that the effect is unlikely to be due to altered kinetics, and most likely reflects a trophic change in spinal opioid action. We are not aware of any studies in which binding was examined with chronic NMDA antagonists exposure. Upregulation of receptor number with chronic antagonism has been reported for several systems, but not, to our knowledge, for NMDA sites. In any case, given the antagonistic effects we would expect from a more efficient NMDA receptor-linked system, increased NMDA sites or glutamate release would not likely account for the enhanced responsiveness to morphine, per se. These results thus raise the possibility that NMDA antagonists may not only prevent the processes that lead to a reduction in morphine sensitivity, but with chronic exposure result in a facilitation of the effects of receptor coupling.
Glutamate is a principal excitatory amino acid acting on the NMDA receptor. If glutamate receptor activity is necessary for, or facilitates development of the tolerant state, then delivery of an opioid should either increase spinal glutamate release or augment receptor effects of resting glutamate levels. In the unanesthetized rat, we have observed that spinal infusion of morphine for 6 days does not affect resting release of spinal excitatory amino acids in dialysate. [27] However, at precipitation of withdrawal, there is a large increase in glutamate release, which is blocked by clonidine and MK801. These results are consistent with the effects observed with opioid tolerance on spinal C-fos activity where acute delivery of systemic morphine has little effect on resting C-fos, although it blocks stimulation evoked increases, [28-30] but during withdrawal there is a massive increase in C-fos activity. [31] Alternatively, if spinal glutamate release is not augmented by morphine then it is possible that the postsynaptic effects are augmented. Activation of the NMDA receptor increases entry of extracellular calcium into the cell, which stimulates the production of nitric oxide. Inhibition of nitric oxide synthetase has been shown to attenuate some signs of withdrawal in morphine-tolerant rats, i.e., wet dog shakes and weight loss. [32] Thus, it is possible that NMDA receptor antagonism could act to prevent tolerance and withdrawal by inhibition of nitric oxide synthetase. Activation of the NMDA receptor also evokes a spinal release of glutamate, which can be blocked by the nitric oxide synthetase inhibitor L-nitro-L-arginine methyl ester. [33].
Back to Top | Article Outline
Spinal N-methyl-D-aspartate Antagonism and Withdrawal
As previously reported with systemic drug delivery, after chronic exposure to morphine, rats displayed a clear hyperalgesia and signs of behavioral agitation directed at the caudal dermatomes of the body during withdrawal. This suggested a hyperalgesic component in the tolerant state. Such hyperpathia has been recently reported by other investigators. [7] With systemic delivery, [1,4] acutely delivered spinal MK801 prevented some (but not all) of these signs, suggesting that during withdrawal there is a particular increase in glutamate release. As noted earlier, we recently showed that, using spinal dialysis in unanesthetized rats, naloxone treatment results in a prominent release of glutamate in animals rendered tolerant to morphine concentrations and treatment schedules identical to those employed here. This occurs with a time course that precisely parallels the withdrawal signs associated with the precipitated abstinence syndrome. Importantly, the observed hyperalgesia during withdrawal and its sensitivity to spinal NMDA antagonism also is consistent with the ability of intrathecal NMDA to evoke hyperalgesia in the nontolerant rat. [34] Importantly, in rats infused concurrently with NMDA antagonists, withdrawal was not observed. Whether this is because MK801 was present and acutely able to prevent the manifestations of withdrawal or because MK801 prevented the evolution of the dependent state and subsequently removed the circumstances leading to abstinence-evoked glutamate release is not known.
Back to Top | Article Outline
Intracellular Mechanisms of Opioid Tolerance and the N-methyl-D-aspartate Receptor
Several changes in the receptor-effector mechanism have been proposed as a cause of tolerance. Morphine by its action at the micro opioid receptor produces an inhibition of adenylate cyclase activity and thus a resultant decrease in cyclic adenosine monophosphate formation. [35] Adenylate cyclase is inactivated or activated respectively by Gi and Gs glutamyl transpeptidase membrane bound proteins. Decreased cyclic adenosine monophosphate levels activate protein kinase C (PKC), and activation of PKC phosphorylates the micro receptor-coupled G inhibitory protein, thereby suppressing its ability to mediate receptor-evoked inhibition of adenylate cyclase [36,37] thus leading to a compensatory increase in adenylate cyclase activity and increased levels of cyclic adenosine monophosphate in turn. [38] Thus, changes in PKC activity or coupling of the micro receptor-effector G protein have been proposed as a mechanism of tolerance. Protein kinase C translocation by NMDA receptor activation has been shown. [39] The functional importance of such translocation in tolerance has been suggested by observations that loss of spinal opioid effect (tolerance) has also been blocked by an agent that prevents this translocation of PKC, i.e., monosialoganglioside (GMI) ganglioside. [40] Such increases in PKC activity could have a variety of effects apart from the interference of G protein coupling, including modulation of Potassium channel activity, [41] which would attenuate the ability of opioids to hyperpolarize membranes, and reduction of the magnesium block of the NMDA receptor. [42] In addition, diacylglycerol via PKC activation diminishes the inhibitory effects of the micro agonist on calcium channel opening. [43-45].
There also is evidence that a glutamate receptor is coupled to the enzyme phospholipase C. This catalyzes the hydrolysis of phosphatidyl inositides to two second messengers: inositol 1,4,5,-triphosphate, which causes the mobilization of intracellular calcium, and diacylglycerol, which activates PKC. [46] Although quisqualate has a similar effect, NMDA does not mobilize intracellular calcium and at most is only a weak stimulator of phosphatidyl inositide turnover. Thus, blockade of the NMDA receptor by MK801 would not be expected to prevent activation of PKC in this manner and this mechanism would not likely account for the prevention of tolerance development.
Back to Top | Article Outline
Spinal Receptor Tolerance and Glutamate
The current studies demonstrate that in the face of stable morphine concentrations, the loss of effect produced by spinal delivery is prevented by antagonism of the NMDA ionophore. As reviewed earlier, this emphasizes the role of glutamate release in the tolerance process. This simple consideration leads to the speculation that increased glutamate release may exacerbate the loss of response to the opioid. Such a consideration has surprising theoretical implications regarding two clinically relevant issues. First, considerable evidence suggests that a variety of pain states, such as observed after the injection of formalin into the paw or carrageenin into the knee, may lead to a hyperalgesia that is reversed by NMDA antagonism. [26,47,48] Consistent with this pharmacology, such stimuli have been shown to be associated with a marked stimulus-dependent increase in spinal glutamate, [33,49-52] which is prevented by opioids. [52] It thus seems appropriate to consider that such pain states might in fact exaggerate the evolution of tolerance. This hypothesis is in direct conflict with previous comments that pain may diminish tolerance development and that this may somehow account for the difference in apparent rates of tolerance development observed in preclinical studies (using acute experimental pain models) and chronic clinical pain states. [53,54] Second, as noted, in the face of transient opioid withdrawal, glutamate may show prominent increases. We thus speculate that in the case of bolus opioid dosing, such peaks and valleys of effect may in itself be associated with an enhanced evolution of the tolerant state. Such consideration would suggest that steady-state drug concentrations may under certain circumstances be superior to bolus delivery. These considerations provide a testable hypothesis with relevance both to our understanding of the neurobiology of drug tolerance as well as to the clinical importance of drug delivery paradigms.
The authors thank Dr. Khem Jhamandas for his help and advice in the withdrawal experiments.
Back to Top | Article Outline
REFERENCES
1. Trujillo KA, Akil H: Inhibition of morphine tolerance and dependance by the NMDA receptor antagonist MK-801. Science 1991; 251:85-7.

2. Marek P, Ben Eliyahu S, Gold M, Liebeskind JC: Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res 1991a; 547:77-81.

3. Marek P, Ben Eliyahu S, Vaccarino AL, Liebeskind JC: Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res 1991b; 558:163-5.

4. Ben Eliyahu S, Marek P, Vaccarino AL, Mogil JS, Sternberg WF, Liebeskind JC: The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res 1992; 575:304-8.

5. Kest B, Marek P, Liebeskind JC: The specific N-methyl- D-aspartate (NMDA) receptor antagonist MK-801 blocks U-50,488 but not morphine antinociception. Brain Res 1992; 589:139-42.

6. Gutstein HB, Trujillo KA, Akil H: MK 801 inhibits the development of morphine tolerance in the rat at spinal sites. (Abstract) Neuroscience 1993; 18:369.

7. Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: Role of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301-12.

8. Kest B, Mogil JS, Shamgar BE, Kao B, Liebeskind JC, Marek P: The NMDA receptor antagonist MK801 protects against the development of morphine tolerance after intrathecal administration. Proc West Pharmacol Soc 1993; 36:307-10.

9. Collingdridge GL, Bliss TVP: NMDA receptors: Their role in long-term potentiation. Trends Neurosci 1987; 10:288-94.

10. Stevens CW, Monasky MS, Yaksh TL: Spinal infusion of opiate and alpha-2 agonists in the rats: Tolerance and cross tolerance studies. J Pharmacol Exp Ther 1988; 244:63-70.

11. Stevens CW, Yaksh TL: Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion. J Pharmacol Exp Ther 1989a; 250:1-8.

12. Stevens CW, Yaksh TL: Time course characteristics of tolerance development to continuously infused antinociceptive agents in rat spinal cord. J Pharmacol Exp Ther 1989; 251:216-23.

13. Sosnowski M, Yaksh TL: Differential cross tolerance between intrathecal morphine and sufentanil in the rat. ANESTHESIOLOGY 73:1141-1147, 1990.

14. Yaksh TL, Rudy TA: Chronic cathetherization of the subarachnoid space. Physiol Behav 1976; 7:1032-6.

15. Yaksh TL, Harty GJ: Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther 1988; 244:501-7.

16. Tiseo PJ, Cheng J, Pasternak GW, Inturrisi CE: Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J Pharmacol Exp Ther 1994; 268:195-201.

17. MacRae JR, Scoles MT, Siegel S: The contribution of Pavlovian conditioning to drug tolerance and dependance. Br J Addict 1987; 82:371-80.

18. Mjanger E, Yaksh TL: Characteristics of the dose dependant antagonism of B-funaltrexamine of the antinociceptive effects of intrathecal mu agonists. J Pharmacol Exp Ther 1991; 258:544-50.

19. Takano Y, Yaksh TL: Relative efficacy of spinal alpha-2 agonists, dexmedetomidine, clonidine and ST91, determined in vivo using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinolone, an irreversible antagonist. J Pharmacol Exp Ther 1991; 258:438-46.

20. Takano Y, Yaksh TL: Characterization of the pharmacology of intrathecally administered alpha-2 agonists and antagonists in rats. J Pharmacol Exp Ther 1992; 261:764-72.

21. Nishino K, Su YF, Wong CS, Watkins WD, Chang KJ: Dissociation of mu opioid tolerance from receptor down-regulation in rat spinal cord. J Pharmacol Exp Ther 1990; 253:67-72.

22. Wong CS, Su YF, Watkins WD, Chang KJ: Continuous opioid treatment abolishes the regulatory effect of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes. J Pharmacol Exp Ther 1992; 262:317-26.

23. Bhargava HN, Gulati A: Down-regulation of brain and spinal cord mu opioid receptors in morphine tolerant dependant. Eur J Pharmacol 1990; 190:305-11.

24. Gourarderes C, Jhamandas K, Cridland R, Cros J, Quirion R, Zajac JM: Opioid and substance P receptor adaptations in the rat spinal cord following subchronic intrathecal treatment with morphine and naloxone. Neuroscience 1993; 54:799-807.

25. Collingridge GL, Lester RA: Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 1989; 41:143-210.

26. Yamamoto T, Yaksh TL: Studies on the spinal interaction of morphine and the NMDA antagonist MK801 on the hyperesthesia observed in the rat model of sciatic mononeuropathy. Neurosci Lett 1992; 135:67-70.

27. Jhamandas K, Marsala M, Yaksh TLY: Spinal release of L-glutamate during naloxone precipitated opioid withdrawal in the unanesthetized rat (abstract). Neuroscience 1994; 20:753.

28. Hammond DL, Presley R, Gogas KR, Basbaum AI: Morphine or U-50,488 suppresses Fos protein-like immunoreactivity in the spinal cord and nucleus tractus solitarii evoked by a noxious visceral stimulus in the rat. J Comp Neurol 1992; 315:244-53.

29. Gogas KR, Levine JD, Basbaum AI: Mechanisms of opioid mediated antinociception: Correlation of Fos expression and behavior. NIDA Res Monogr 1993; 125:134-60.

30. Tolle TR, Castro-Lopes JM, Coimbra A, Zieglgansberger W: Opiates modify induction of c-fos proto-oncogene in the spinal cord of the rat following noxious stimulation. Neurosci Lett 1990; 111:46-51.

31. Hayward MD, Duman RS, Nestler EJ: Induction of the c-fos proto-oncogene during opiate withdrawal in the locus coeruleus and other regions of the rat brain. Brain Res 1990; 525:256-66.

32. Kimes AS, Vaupel DB, London ED: Attenuation of some signs of opiod withdrawal by inhibitors of nitric oxide synthetase. Psychopharmacology 1993; 112:521-4.

33. Sorkin LS: NMDA evokes an L-NAME sensitive spinal release of glutamate and citrulline. Neuroreport 1993; 4:479-82.

34. Malmberg AB, Yaksh TL: The effect of morphine on formalin-evoked behaviour and spinal release of excitatory amino acids and prostaglandin E sub 2 using microdialysis in conscious rats. Br J Pharmacol 1995; 114:1069-75.

35. Bachrach U, Benalal D, Reches A: Morphine inhibits cyclic AMP-dependent protein kinase and ornithine decarboxylase activities in neuroblastoma X glioma hybrid cells. Life Sci 1979; 25:1879-83.

36. Nestler E: Cellular responses to chronic treatment with drugs of abuse. Crit Rev Neurobiol 1993; 7:23-39.

37. Katada T, Gilman AG, Watanabe Y, Bauer S, Jakobs KH: Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. Eur J Biochem S 1985; 151:431-7.

38. Sharma SK, Klee WA, Nirenberg M: Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Nat Acad Sci U S A 1975; 72:3092-6.

39. Etoh S, Baba A, Iwata H: NMDA induces protein kinase C in hippocampal slices of immature rat brain. Neurosci Lett 1992; 126:119-22.

40. Mayer DJ, Mao J, Price DD: The development of morphine tolerance is associated with increases in membrane bound protein kinase C: Prevention by GM1 ganglioside (abstract). Soc Neurosci Abst 1993; 19:1796.

41. Alkon DL, Naito S: Long term synergistic regulation of ionic channels by C-kinase and Calcium 2+/Calcium M-type 11 kinase. Adv Exp Med Biol 1987; 221:275-90.

42. Chen L, Huang LY: Protein kinase C reduces Magnesium 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 1992; 356:521-3.

43. Rane SG, Dunlap K: Kinase C activator 1,2-oleoylacetylglycerol attenuates voltage-dependent calcium current in sensory neurons. Proc Nat Acad Sci U S A 1986; 83:184-8.

44. Ewald DA, Pang IH, Sternweis PC, Miller RJ: Differential G protein-mediated coupling of neurotransmitter receptors to Calcium 2+ channels in rat dorsal root ganglion neurons in vitro. Neuron 1989; 2:1185-93.

45. Ewald DA, Matthies HJ, Perney TM, Walker MW, Miller RJ: The effect of down regulation of protein kinase C on the inhibitory modulation of dorsal root ganglion neuron Calcium 2+ currents by neuropeptide Y. J Neurosci 1988; 8:2447-51.

46. Berridge MJ, Irvine RF: Inositol triphosphate, a novel second messanger in cellular signal transduction. Nature 1984; 312:315-21.

47. Neugebauer V, Lucke T, Schaible HG: N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists block the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat's knee joint. J Neurophysiol 1993; 70:1365-77.

48. Yamamoto T, Yaksh TL: Comparison of the antinociceptive effects of pre- and post-treatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat. ANESTHESIOLOGY 1992; 77:757-63.

49. Sorkin LS: Experimental arthritis alters C-fiber evoked amino acid release in spinal cord (abstract). ANESTHESIOLOGY 1994; 81:918.

50. Sanghvi R, Yaksh, TL: Spinal amino acid release evoked by paw formalin in unanesthetized and halothane anesthetized rats. ANESTHESIOLOGY 1994; 81:836.

51. Malmberg AB, Yaksh TL: Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992b; 257:1276-9.

52. Colpaert FC, Niemegeers CJ, Janssen PA: Nociceptive stimulation prevents development of tolerance to narcotic analgesia. Eur J Pharmacol 1978; 49:335-6.

53. Colpaert FC, Niemegeers CJ, Janssen PA, Maroli AN: The effects of prior fentanyl administration and of pain on fentanyl analgesia: Tolerance to and enhancement of narcotic analgesia. J Pharmacol Exp Ther 1980; 213:418-24.

54. Abbott FV, Melzack R, Leber BF: Morphine analgesia and tolerance in the tail-flick and formalin tests: Dose-response relationships. Pharm Biochem Behav 1982; 17:1213-9.

Keywords:
Analgesics, narcotic: dependence; morphine; spinal; tolerance. Receptors: N-methyl-D-aspartate.

© 1996 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Images

Share